SG11201809751XA - Egfr inhibitor compounds - Google Patents
Egfr inhibitor compoundsInfo
- Publication number
- SG11201809751XA SG11201809751XA SG11201809751XA SG11201809751XA SG11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- cure
- road
- international
- san diego
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/36—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) iii 1111111111111111111111111111111111111111111111111111110111111111111111111111111111111111 (10) International Publication Number WO 2017/205459 Al WIPO I PCT (51) International Patent Classification: CO7D 403/14 (2006.01) A61K 31/404 (2006.01) CO7D 209/04 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/034163 (22) International Filing Date: 24 May 2017 (24.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/342,141 26 May 2016 (26.05.2016) US (71) Applicant: KALYRA PHARMACEUTICALS, INC. [US/US]; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). (72) Inventors: BUNKER, Kevin, Duane; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). HUANG, Peter, Qinhua; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). ABRAHAM, Sunny; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). PINCHMAN, Joseph, Robert; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). HOPKINS, Chad, Daniel; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). SLEE, Deborah, Helen; 10835 Road To The Cure, Suite 205, Sab Diego, CA 92121 (US). (74) Agent: MILLIER, Kimberely, J.; Knobbe, Martens, Ol- son & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1-1 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 71' O TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 2 I (3)) N (54) Title: EGFR INHIBITOR COMPOUNDS 0 (57) : Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods \" of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342141P | 2016-05-26 | 2016-05-26 | |
PCT/US2017/034163 WO2017205459A1 (en) | 2016-05-26 | 2017-05-24 | Egfr inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809751XA true SG11201809751XA (en) | 2018-12-28 |
Family
ID=60411884
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202102920QA SG10202102920QA (en) | 2016-05-26 | 2017-05-24 | Egfr inhibitor compounds |
SG11201809751XA SG11201809751XA (en) | 2016-05-26 | 2017-05-24 | Egfr inhibitor compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202102920QA SG10202102920QA (en) | 2016-05-26 | 2017-05-24 | Egfr inhibitor compounds |
Country Status (15)
Country | Link |
---|---|
US (3) | US10513509B2 (en) |
EP (1) | EP3464275A4 (en) |
JP (1) | JP7030066B2 (en) |
KR (2) | KR102444835B1 (en) |
CN (2) | CN112624954A (en) |
AR (1) | AR110038A1 (en) |
AU (2) | AU2017269335B2 (en) |
BR (1) | BR112018074232A2 (en) |
CA (1) | CA3023176A1 (en) |
IL (2) | IL263081B (en) |
MX (2) | MX2018013413A (en) |
RU (1) | RU2751341C2 (en) |
SG (2) | SG10202102920QA (en) |
TW (1) | TWI752033B (en) |
WO (1) | WO2017205459A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
CN108864079B (en) * | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | Triazine compound and pharmaceutically acceptable salt thereof |
WO2019051038A1 (en) | 2017-09-11 | 2019-03-14 | Zeno Royalties & Milestones, LLC | Continuous flow processes for making bicyclic compounds |
CN110041302B (en) * | 2019-03-01 | 2021-11-30 | 南方医科大学 | 2-amino-4-substituted pyridine derivative and synthesis method and application thereof |
CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
CN112292378B (en) * | 2019-05-22 | 2024-02-06 | 上海翰森生物医药科技有限公司 | Indole derivative-containing inhibitor, preparation method and application thereof |
WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4169915A1 (en) * | 2020-06-23 | 2023-04-26 | Shenzhen Forward Pharmaceuticals Co., Limited | Crystalline form of compound |
CN117561254A (en) * | 2021-04-30 | 2024-02-13 | 苏州浦合医药科技有限公司 | Pyrimidinylaminobenzene for lung cancer treatment |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1051350A (en) | 1910-02-02 | 1913-01-21 | Thomas Nogier | Apparatus for the sterilization of liquids. |
DE4124942A1 (en) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS |
JPH08503971A (en) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | Pyrimidineamine derivatives and methods for their preparation |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
ES2271283T3 (en) * | 2001-07-03 | 2007-04-16 | Vertex Pharmaceuticals Incorporated | ISOXAZOLIL-PIRIMIDINAS AS INHIBITORS OF THE PROTEINAS QUINASAS SRC AND LCK. |
US7396940B2 (en) | 2003-10-23 | 2008-07-08 | Hoffmann-La Roche Inc. | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid |
EP1773807A2 (en) | 2004-06-14 | 2007-04-18 | Takeda San Diego, Inc. | Kinase inhibitors |
CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
JP4638512B2 (en) | 2005-03-04 | 2011-02-23 | メルク・シャープ・エンド・ドーム・コーポレイション | Condensed aromatic compounds having anti-diabetic activity |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
AU2007261440A1 (en) | 2006-06-22 | 2007-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
WO2008137105A1 (en) | 2007-05-07 | 2008-11-13 | Merck & Co., Inc. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
JP2010031249A (en) | 2008-06-23 | 2010-02-12 | Sumitomo Chemical Co Ltd | Composition and light-emitting element using the composition |
JP2011526299A (en) | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス, インコーポレイテッド | Heteroaryl compounds and their use |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
CN101723936B (en) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | Kinase suppressor and pharmaceutical application thereof |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
CA2773848A1 (en) | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
KR101116234B1 (en) | 2009-10-29 | 2014-03-06 | (주)퓨쳐켐 | Aryl derivatives substituted with (3-fluoro-2-hydroxy)propyl group or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient |
TW201219383A (en) | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
US8940739B2 (en) | 2010-10-14 | 2015-01-27 | Jw Pharmaceutical Corporation | Compound of a reverse-turn mimetic and a production method and use therefor |
CA2827161A1 (en) | 2011-03-16 | 2012-09-20 | F. Hoffmann-La Roche Ag | 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
WO2012126181A1 (en) | 2011-03-24 | 2012-09-27 | Ying Luo | Use of kinase inhibitors in preventing and treating inflammatory disorder |
CN104109161B (en) * | 2011-07-27 | 2016-08-17 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted aniline) pyrimidine derivatives is used for treating cancer as EGFR modulator |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
JP6399660B2 (en) | 2012-04-10 | 2018-10-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Cancer treatment compositions and methods |
CN103508961B (en) | 2012-06-26 | 2015-07-22 | 中美冠科生物技术(太仓)有限公司 | Antitumor drug |
WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
HUE052548T2 (en) | 2012-11-21 | 2021-05-28 | Janssen Biotech Inc | Bispecific egfr/c-met antibodies |
WO2014178606A1 (en) | 2013-04-29 | 2014-11-06 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
US20180057603A1 (en) | 2013-08-09 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers |
US10370371B2 (en) | 2013-08-30 | 2019-08-06 | Ptc Therapeutics, Inc. | Substituted pyrimidine Bmi-1 inhibitors |
CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
CN106232625B (en) | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | Methods of treating and diagnosing α -V- β -6 overexpressing cancers |
GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
CN104761544B (en) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | The selective depressant of the important mutant of clinic of EGFR tyrosine kinase |
WO2015112705A2 (en) | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
CN104860941B (en) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative |
CN104876914B (en) | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | Pyrimidine derivative type anaplastic lymphoma kinase inhibitor |
TW201622744A (en) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | Combination therapy for cancer |
CN104892585B (en) | 2014-03-06 | 2018-07-03 | 山东轩竹医药科技有限公司 | Pyrimidine derivates species anaplastic lymphoma kinase inhibitor |
ES2890556T3 (en) | 2014-04-04 | 2022-01-20 | Astrazeneca Ab | Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of NRAS-mutated cancer |
SG10201809260XA (en) | 2014-04-04 | 2018-11-29 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015175965A1 (en) | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
CN111875585B (en) | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | Kinase inhibitors |
AP2017009690A0 (en) * | 2014-06-19 | 2017-01-31 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
CN105254615B (en) | 2014-07-11 | 2017-02-22 | 杭州华东医药集团新药研究院有限公司 | Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers |
BR112017000316A2 (en) | 2014-07-11 | 2017-10-31 | Genmab As | antibody, immunoconjugate, composition, nucleic acid construct, expression vector, hybridoma, methods for treating cancer, to diagnose a disease, inhibit growth and / or proliferation of a cell tumor, and produce an antibody, use, and kit. ? |
CN105315285B (en) | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4 2 substitution 7H pyrrolo-es [2,3 d] pyrimidine derivatives, its preparation method and purposes pharmaceutically |
EP3180344B1 (en) * | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
EP3180029A1 (en) | 2014-08-15 | 2017-06-21 | Boehringer Ingelheim International GmbH | Afatinib pharmaceutical kit for cancer treatment |
CN104140418B (en) | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2,4,5-substituted aniline) pyrimidine derivatives and application thereof |
CN113121575A (en) | 2014-08-25 | 2021-07-16 | 四川海思科制药有限公司 | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof |
JPWO2016032003A1 (en) | 2014-08-30 | 2017-07-13 | 国立大学法人金沢大学 | Lung cancer patient therapeutic agent and method for predicting the effectiveness of lung cancer patient treatment |
AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
WO2016040622A1 (en) | 2014-09-11 | 2016-03-17 | Bulldog Pharmaceuticals, Inc. | Uses of anti-her3 antibodies for treating cancer |
WO2016045799A1 (en) | 2014-09-26 | 2016-03-31 | Hi-Stem Ggmbh | Novel methods for sub-typing and treating cancer |
CN105461695B (en) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | Pyrimidine or pyrrolotriazine derivatives and its production and use |
CN105237515B (en) | 2014-10-10 | 2018-06-05 | 益方生物科技(上海)有限公司 | Deuterated pyrimidines, its preparation method, pharmaceutical composition and purposes |
CN106661000B (en) * | 2014-10-11 | 2019-04-09 | 上海翰森生物医药科技有限公司 | EGFR inhibitor and its preparation and application |
EP3604294B1 (en) * | 2014-10-13 | 2021-05-05 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN111170998B (en) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | Pyrimidine or pyridine compound, preparation method and medical application thereof |
WO2016090174A1 (en) | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
CA2970185C (en) | 2014-12-11 | 2023-10-17 | Beta Pharma, Inc. | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
WO2016105582A1 (en) | 2014-12-24 | 2016-06-30 | Nunn Philip A | Compositions for ileo-jejunal drug delivery |
WO2016112302A1 (en) | 2015-01-09 | 2016-07-14 | Metastat, Inc. | Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor |
US20180271853A1 (en) | 2015-01-09 | 2018-09-27 | Metastat, Inc. | Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant III |
AU2016216253B2 (en) | 2015-02-04 | 2019-11-21 | Beyondbio Inc. | Heterocyclic compound and pharmaceutical composition comprising same |
JP2018504418A (en) | 2015-02-05 | 2018-02-15 | ティルノーヴォ リミテッド | Combination of an IRS / STAT3 dual modifier and an anticancer agent for the treatment of cancer |
CN104961731A (en) | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof |
CN105985323A (en) | 2015-02-15 | 2016-10-05 | 宁波文达医药科技有限公司 | Novel epidermal growth factor receptor inhibitor and application thereof |
WO2016141324A2 (en) | 2015-03-05 | 2016-09-09 | Trovagene, Inc. | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids |
CN106138020A (en) | 2015-04-03 | 2016-11-23 | 中国人民解放军第三军医大学第三附属医院 | Biguanides prevents in preparation or weakens the application in the medicine of pulmonary fibrosis |
CN106138061B (en) | 2015-04-03 | 2019-06-04 | 中国人民解放军第三军医大学第三附属医院 | The compound and its preparation and purposes of prevention or decrease pulmonary fibrosis |
WO2016164217A1 (en) | 2015-04-09 | 2016-10-13 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
CN104844580B (en) | 2015-04-17 | 2017-10-20 | 中国药科大学 | Pyrimidines, its preparation method and medical usage |
JP2018513178A (en) | 2015-04-23 | 2018-05-24 | メディミューン リミテッド | Combination therapy of non-small cell lung cancer positive for EGFR gene mutation |
CN104817541B (en) | 2015-05-11 | 2017-06-16 | 苏州东南药业股份有限公司 | A kind of synthetic method of antineoplastic |
JP6949726B2 (en) | 2015-05-15 | 2021-10-13 | ノバルティス アーゲー | How to treat EGFR mutant cancer |
AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
US20180117053A1 (en) | 2015-05-27 | 2018-05-03 | Metastat, Inc. | The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI |
AU2016270375B2 (en) | 2015-06-03 | 2021-05-13 | Chang Gung Medical Foundation Keelung Chang Gung Memorial Hospital | Methods and compositions for treating non-small cell lung cancer |
US20160355503A1 (en) | 2015-06-04 | 2016-12-08 | Cleave Biosciences, Inc. | NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CN104910049B (en) | 2015-06-16 | 2016-06-29 | 苏州明锐医药科技有限公司 | AZD9291 intermediate and preparation method thereof |
JP6892431B2 (en) | 2015-07-10 | 2021-06-23 | ゲンマブ エー/エス | AXL-Specific Antibodies-Drug Conjugates for Cancer Treatment |
DK3325662T3 (en) | 2015-07-17 | 2023-11-27 | Pacylex Pharmaceuticals Inc | EPIGENETIC INACTIVATION OF NMT2 |
US10550112B2 (en) | 2015-07-20 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
TW201716439A (en) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | HER3 antibodies |
EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
CN107531678B (en) | 2015-07-24 | 2020-12-22 | 上海海雁医药科技有限公司 | EGFR inhibitor and pharmaceutically acceptable salts and polymorphs thereof and uses thereof |
CN105001208A (en) | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | EGFR inhibitor and preparing method and application thereof |
US10980765B2 (en) | 2015-08-14 | 2021-04-20 | Board Of Supervisors Of Louisiana State University | Isothiocyanatostilbenes as a novel method and product for treating cancer |
CN105153122B (en) | 2015-08-27 | 2018-07-20 | 上海圣考医药科技有限公司 | [(indol-3-yl) pyrimidine -2-base] aminophenyl propyl- 2- alkenylamide derivatives and salt, preparation method, application |
CN110483485A (en) | 2015-09-02 | 2019-11-22 | 益方生物科技(上海)有限公司 | Pyrimidines, preparation method and medical usage |
CN105126125A (en) | 2015-09-12 | 2015-12-09 | 复旦大学 | Zinc oxide-gadolinium-drug composite nanoparticle, and preparation method and application thereof |
AU2016328764B2 (en) | 2015-09-25 | 2020-07-09 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Compounds and methods for inhibiting JAK |
US10308658B2 (en) | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
US20170115275A1 (en) | 2015-10-23 | 2017-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development |
WO2017075367A1 (en) | 2015-10-28 | 2017-05-04 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
EP3370715A4 (en) | 2015-11-02 | 2019-05-15 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
CN106674202A (en) | 2015-11-05 | 2017-05-17 | 惠州信立泰药业有限公司 | Dimethyl sulfonate of compound A, crystal form of dimethyl sulfonate, and medicinal composition containing dimethyl sulfonate |
CN106699736A (en) | 2015-11-17 | 2017-05-24 | 惠州信立泰药业有限公司 | Crystal form gamma of compound A mesylate and pharmaceutical composition containing the same |
CN105294717B (en) | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | A kind of salt of EGFR inhibitor, crystal formation and application thereof |
CN105461729B (en) | 2015-11-18 | 2017-12-05 | 乳源瑶族自治县大众药品贸易有限公司 | A kind of salt of EGFR inhibitor, crystal formation and application thereof |
RU2603960C1 (en) | 2015-11-19 | 2016-12-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Dichloroacetate of n1,n2-disubstituted n4-[4-(1-methyl-1h-indole-3-yl)-pyrimidine-2-yl]-5-methoxybenzene-1,2,4-triamine as egfr modulator for treating cancer |
RU2606949C9 (en) | 2015-11-19 | 2018-03-14 | ЗАО "Р-Фарм" | Substituted n-{3-[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-amides as modulators of egfr, applicable for treating cancer |
CN105348267A (en) | 2015-12-01 | 2016-02-24 | 中山奕安泰医药科技有限公司 | Method for synthesizing AZD9291 intermediate |
US10844074B2 (en) | 2015-12-03 | 2020-11-24 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocycle compounds and uses thereof |
US10829495B2 (en) | 2015-12-03 | 2020-11-10 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Thieno-pyrimidine derivatives and uses thereof |
WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
TWI623316B (en) | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
CN105601620A (en) | 2015-12-25 | 2016-05-25 | 北京康立生医药技术开发有限公司 | Method for preparing mereletinib mesylate |
KR102029135B1 (en) | 2015-12-27 | 2019-10-07 | 뉴폼 파마슈티컬스, 아이엔씨. | Deuterated compounds, compositions and methods thereof for treating cancer and related diseases and conditions |
CN106928150B (en) | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技(上海)有限公司 | Acrylamide aniline derivative and pharmaceutical application thereof |
CN109328059B (en) | 2016-01-07 | 2021-08-17 | Cs制药技术有限公司 | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase |
EP3399966B1 (en) | 2016-01-08 | 2023-03-29 | The Regents of the University of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
JP6942726B2 (en) | 2016-01-08 | 2021-09-29 | ユークリセス ファーマシューティカルズ,インコーポレイテッド | Combination drug of chromene compound and second active drug |
CN105646454B (en) | 2016-01-19 | 2018-05-08 | 浙江大学 | The 2- aryl amine pyridine derivatives of the fragment containing hydroxamic acid and preparation and application |
TWI745345B (en) | 2016-02-01 | 2021-11-11 | 瑞典商阿斯特捷利康公司 | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and “azd9291 aniline” or a salt thereof |
WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
US10806716B2 (en) | 2016-02-04 | 2020-10-20 | Auransa Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
CN108601781B (en) | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | As the 3,5- disubstituted pyrazole of test point kinases 1 (CHK1) inhibitor and its preparation and application |
CN105777716B (en) | 2016-02-25 | 2018-04-10 | 清华大学 | A kind of EGFR inhibitor for targeted therapy of cancer and preparation method and application |
CN105585557B (en) | 2016-02-25 | 2018-06-22 | 清华大学 | EGFR inhibitor for targeted therapy of cancer and preparation method and application |
AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
CN105886648A (en) | 2016-06-06 | 2016-08-24 | 武汉海吉力生物科技有限公司 | Kit used for detecting T790M mutation of EGFR gene |
CN106366022B (en) | 2016-08-19 | 2018-03-13 | 上海工程技术大学 | It is a kind of to be used to prepare AZD9291 intermediate and its preparation method and application |
CN106366072B (en) | 2016-08-19 | 2018-12-07 | 上海工程技术大学 | A kind of preparation method of AZD9291 |
CN106397407B (en) | 2016-08-31 | 2018-09-04 | 浙江科聚化工有限公司 | The preparation method of antitumor drug AZD9291 derivatives |
CN106432231B (en) | 2016-09-09 | 2018-06-12 | 无锡佰翱得生物科学有限公司 | The pharmaceutical salts and its crystal form and preparation method of AZD9291 |
CN106565522A (en) | 2016-09-29 | 2017-04-19 | 福格森(武汉)生物科技股份有限公司 | Method for preparing alkyloxy aromatic compound from fluoroaromatic compound |
CN106496196B (en) | 2016-10-20 | 2019-07-02 | 南京雷科星生物技术有限公司 | A kind of quinazoline, Pyridopyrimidine or double and pyrimidine derivatives egf inhibitor and preparation method thereof and purposes |
CN106543060B (en) | 2016-10-31 | 2018-11-06 | 湖南欧亚药业有限公司 | A kind of difficult to understand this replaces the preparation method of Buddhist nun's mesylate |
CN106668866A (en) | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | Medicinal composition for resisting non-small cell lung cancer, and application thereof |
CN106883216B (en) | 2017-04-06 | 2020-03-13 | 张家港威胜生物医药有限公司 | Preparation method of oxitinib |
-
2017
- 2017-05-24 AU AU2017269335A patent/AU2017269335B2/en active Active
- 2017-05-24 SG SG10202102920QA patent/SG10202102920QA/en unknown
- 2017-05-24 CN CN202011563825.6A patent/CN112624954A/en active Pending
- 2017-05-24 US US15/603,789 patent/US10513509B2/en active Active
- 2017-05-24 JP JP2018561695A patent/JP7030066B2/en active Active
- 2017-05-24 BR BR112018074232-5A patent/BR112018074232A2/en active Search and Examination
- 2017-05-24 AR ARP170101409A patent/AR110038A1/en unknown
- 2017-05-24 EP EP17803481.5A patent/EP3464275A4/en active Pending
- 2017-05-24 RU RU2018138584A patent/RU2751341C2/en active
- 2017-05-24 CA CA3023176A patent/CA3023176A1/en active Pending
- 2017-05-24 KR KR1020187034187A patent/KR102444835B1/en active IP Right Grant
- 2017-05-24 CN CN201780032202.6A patent/CN109311858B/en active Active
- 2017-05-24 WO PCT/US2017/034163 patent/WO2017205459A1/en unknown
- 2017-05-24 MX MX2018013413A patent/MX2018013413A/en unknown
- 2017-05-24 SG SG11201809751XA patent/SG11201809751XA/en unknown
- 2017-05-24 KR KR1020227031434A patent/KR20220130249A/en not_active Application Discontinuation
- 2017-05-25 TW TW106117475A patent/TWI752033B/en active
-
2018
- 2018-11-01 MX MX2021007773A patent/MX2021007773A/en unknown
- 2018-11-18 IL IL263081A patent/IL263081B/en active IP Right Grant
-
2019
- 2019-12-04 US US16/703,544 patent/US11098030B2/en active Active
-
2021
- 2021-03-16 IL IL281537A patent/IL281537A/en unknown
- 2021-08-17 US US17/445,280 patent/US20210395230A1/en active Pending
- 2021-09-29 AU AU2021240162A patent/AU2021240162A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201807708SA (en) | Estrogen receptor modulators | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201900904PA (en) | Methods for cross coupling | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810872UA (en) | Composition and method for reducing neutropenia |